A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

(2016) Angelica Loskog et al.   BRITISH JOURNAL OF CANCER

The use of pembrolizumab for the treatment of metastatic uveal melanoma

(2016) Lisa A. Kottschade et al.   MELANOMA RESEARCH

Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients

(2015) Xinan Sheng et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

(2015) Lisa Zimmer et al.   Journal of Translational Medicine

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

(2015) Lisa Zimmer et al.   PLoS One

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

(2014) Grant A McArthur et al.   LANCET ONCOLOGY

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

(2013) M. Maio et al.   ANNALS OF ONCOLOGY

Conjunctival Melanomas Harbor BRAF and NRAS Mutations--Response

(2013) K. G. Griewank et al.   CLINICAL CANCER RESEARCH

Conjunctival Melanomas Harbor BRAF and NRAS Mutations--Letter

(2013) J. L. Weber et al.   CLINICAL CANCER RESEARCH

Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

(2013) K. G. Griewank et al.   CLINICAL CANCER RESEARCH

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

(2013) Paolo A. Ascierto et al.   JOURNAL OF CLINICAL ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma

(2010) Helena Pópulo et al.   MELANOMA RESEARCH

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape

(2009) Aleksandar Sekulic et al.   MAYO CLINIC PROCEEDINGS

Mortality after uveal and conjunctival melanoma: which tumour is more deadly?

(2008) Emma Kujala et al.   ACTA OPHTHALMOLOGICA